GIMBHI’s daily mental health update — 7/23/26

🍄 Eli Lilly acquires 5-MeO-DMT developer AtaiBeckley for up to $3.8 billion (Josh Hardman, Psychedelic Alpha) — 07/16/26
TL;DR: Eli Lilly is acquiring AtaiBeckley for ~$2.8B upfront plus up to $1B in milestones, the largest psychedelic buyout yet, gaining Phase 3 intranasal 5-MeO-DMT (BPL-003) and DMT candidate VLS-01 for treatment-resistant depression.

💊 Draig Therapeutics closes oversubscribed $65M Series B for AMPA and GABAA receptor modulators (Business Wire) — 07/14/26
TL;DR: Draig Therapeutics raised an oversubscribed $65M Series B led by Deep Track Capital to advance its neuropsychiatric pipeline, including lead candidate DT-101, an AMPA receptor potentiator in Phase 2 for major depressive disorder.

🧠 Hemispheric emerges from stealth with $52M to launch Descartes, a frontier NeuroAI brain-decoding model (Business Wire) — 07/15/26
TL;DR: Tel Aviv-based Hemispheric emerged from stealth with $52M to launch Descartes, a NeuroAI model that decodes EEG brain activity into objective diagnostics, targeting PTSD, depression, schizophrenia, and Alzheimer’s.

💊 Alto Neuroscience launches $93.9M stock offering at $26.48 in BofA-led underwriting (TradingView) — 07/14/26
TL;DR: Alto Neuroscience is selling ~3.8M shares at $26.48 in a registered direct offering for roughly $93.9M net, funding accelerated clinical development of ALTO-207, including an additional planned Phase 3 trial, plus working capital.